Relmada Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 23, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	257	15	113	98	549	426
Market Cap Growth	2235.68%	-86.56%	14.70%	-82.10%	28.99%	-13.82%
Enterprise Value	245	-37	17	-74	472	325
Last Close Price	3.60	0.36	-	-	-	-
PB Ratio	31.87	0.44	1.46	0.75	3.00	4.93
P/TBV Ratio	31.87	0.44	1.46	0.75	3.00	4.93
Net Debt / Equity Ratio	-1.47	-1.26	-1.13	-1.06	-1.02	-1.11
Net Debt / EBITDA Ratio	-	-	-	0.92	1.69	1.97
Net Debt / FCF Ratio	0.35	0.87	1.87	1.43	2.31	4.21
Quick Ratio	2.68	4.36	7.90	11.94	14.08	9.30
Current Ratio	2.86	4.45	8.00	12.26	14.83	9.37
Return on Equity (ROE)	-196.79%	-132.33%	-87.51%	-90.07%	-80.14%	-53.74%
Return on Assets (ROA)	-102.41%	-73.14%	-51.76%	-53.57%	-46.01%	-31.52%
Return on Capital Employed (ROCE)	-597.10%	-236.10%	-121.50%	-114.80%	-60.40%	-56.20%
Earnings Yield	-18.62%	-509.73%	-79.28%	-149.50%	-20.13%	-11.42%
FCF Yield	-	-329.85%	-41.46%	-98.81%	-14.71%	-5.34%
Buyback Yield / Dilution	-5.32%	-0.21%	-1.59%	-68.80%	-12.56%	-68.97%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.